ERCC1 as a biomarker for bladder cancer patients likely to benefit from adjuvant chemotherapy

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Sun, Jong Mu ^a   Sung, Ji Youn ^a   Park, Se H ^a   Kwon, Ghee Y ^a   Jeong, Byong C ^a   Seo, Seong I ^a   Jeon, Seong S ^a   Lee, Hyun M ^a   Jo, Jisuk ^b   Choi, Han Y ^a   Lim, Ho Y ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Samsung Medical Center   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GEMCITABINE;

ADULT; AGED; ARTICLE; BLADDER CANCER; BLADDER SURGERY; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PREDICTIVE VALUE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SURVIVAL TIME; TRANSITIONAL CELL CARCINOMA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL MARKERS; CHEMOTHERAPY, ADJUVANT; DNA-BINDING PROTEINS; ENDONUCLEASES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 84861215711     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-187     Document Type: Article

References (24)

1. Sherif A, Rintala E, Mestad O, Nilsson J, Holmberg L, Nilsson S, Malmström P-U. Neoadjuvant cisplatin-methotrexate chemotherapy for invasive bladder cancer - nordic cystectomy trial 2. Scand J Urol Nephrol 2002, 36(6):419-425. 10.1080/003655902762467567, 12623505.
2. Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, White R, Sarosdy MF, Wood DP, Raghavan D, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Eng J Med 2003, 349(9):859-866.
3. Griffiths G, Hall R, Sylvester R, Raghavan D, Parmar MK. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol 2011, 29(16):2171-2177. 3107740, 21502557.
4. Claire LV. Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data: advanced bladder cancer (abc) meta-analysis collaboration. Eur Urol 2005, 48(2):189-201. 10.1016/j.eururo.2005.04.005, 15939530.
5. Ruggeri EM, Giannarelli D, Bria E, Carlini P, Felici A, Nelli F, Gallucci M, Cognetti F, Pollera CF. Adjuvant chemotherapy in muscle-invasive bladder carcinoma. Cancer 2006, 106(4):783-788. 10.1002/cncr.21676, 16419069.
6. Cognetti F, Ruggeri EM, Felici A, Gallucci M, Muto G, Pollera CF, Massidda B, Rubagotti A, Giannarelli D, Boccardo F, et al. Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial. Ann Oncol 2012, 23(3):695-700. 10.1093/annonc/mdr354, 21859900.
7. Paz-Ares L, Solsona E, Esteban E, Gonzalez-Larriba J, Anton A, Hevia M, Guillem V, Rosa F, Bellmunt J. Randomized phase III trial comparing adjuvant paclitaxel/gemcitabine/cisplatin (PGC) to observation in patients with resected invasive bladder cancer: Results of the Spanish Oncology Genitourinary Group (SOGUG) 99/01 study. J Clin Oncol 2010, 28(suppl):7. s (Abstr LBA4518).
8. Stadler WM, Lerner SP, Groshen S, Stein JP, Shi S-R, Raghavan D, Esrig D, Steinberg G, Wood D, Klotz L, et al. Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status. J Clin Oncol 2011, 29(25):3443-3449. 10.1200/JCO.2010.34.4028, 21810677.
9. Studer UE, Bacchi M, Biedermann C, Jaeger P, Kraft R, Mazzucchelli L, Markwalder R, Senn E, Sonntag RW. Adjuvant cisplatin chemotherapy following cystectomy for bladder cancer: results of a prospective randomized trial. J Urol 1994, 152(1):81-84.
10. David KA, Milowsky MI, Ritchey J, Carroll PR, Nanus DM. Low incidence of perioperative chemotherapy for stage iii bladder cancer 1998 to 2003: a report from the national cancer data base. J Urol 2007, 178(2):451-454. 10.1016/j.juro.2007.03.101, 17561135.
11. Hussain MHA, Wood DP, Bajorin DF, Bochner BH, Dreicer R, Lamm DL, O'Donnell MA, Siefker-Radtke AO, Theodorescu D, Dinney CP. Bladder cancer: narrowing the gap between evidence and practice. J Clin Oncol 2009, 27(34):5680-5684. 10.1200/JCO.2009.23.6901, 19858384.
12. Lord RV, Brabender J, Gandara D, Alberola V, Camps C, Domine M, Cardenal F, Sanchez JM, Gumerlock PH, Taron M, et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 2002, 8(7):2286-2291.
13. Selvakumaran M, Pisarcik DA, Bao R, Yeung AT, Hamilton TC. Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines. Cancer Res 2003, 63(6):1311-1316.
14. Ceppi P, Volante M, Novello S, Rapa I, Danenberg KD, Danenberg PV, Cambieri A, Selvaggi G, Saviozzi S, Calogero R, et al. ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann Oncol 2006, 17(12):1818-1825. 10.1093/annonc/mdl300, 16980606.
15. Olaussen KA, Dunant A, Fouret P, Brambilla E, Andre F, Haddad V, Taranchon E, Filipits M, Pirker R, Popper HH, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006, 355(10):983-991. 10.1056/NEJMoa060570, 16957145.
16. Sun J-M, Ahn M-J, Park MJ, Lee H-Y, Ahn JS, Lee S, Kang G, Han J, Son Y-I, Baek C-H, et al. Expression of Excision Repair Cross-Complementation Group 1 as Predictive Marker for Nasopharyngeal Cancer Treated With Concurrent Chemoradiotherapy. Int J Radiat Oncol Biol Phys 2011, 80(3):655-660. 10.1016/j.ijrobp.2010.02.061, 21621119.
17. Hwang IG, Ahn MJ, Park BB, Ahn YC, Han J, Lee S, Kim J, Shim YM, Ahn JS, Park K. ERCC1 expression as a prognostic marker in N2(+) nonsmall-cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy. Cancer 2008, 113(6):1379-1386. 10.1002/cncr.23693, 18623378.
18. Simon GR, Sharma S, Cantor A, Smith P, Bepler G. ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest 2005, 127(3):978-983. 10.1378/chest.127.3.978, 15764785.
19. Rosell R, Pifarré A, Monzó M, Astudillo J, López-Cabrerizo MP, Calvo R, Moreno I, Sánchez-Céspedes M, Font A, Navas-Palacios JJ. Reduced survival in patients with stage-I non-small-cell lung cancer associated with DNA-replication errors. Int J Cancer 1997, 74(3):330-334. 10.1002/(SICI)1097-0215(19970620)74:3<330::AID-IJC17>3.0.CO;2-F, 9221814.
20. Kim KH, Do I-G, Kim HS, Chang MH, Kim HS, Jun HJ, Uhm J, Yi SY, Lim DH, Ji SH, et al. Excision repair cross-complementation group 1 (ERCC1) expression in advanced urothelial carcinoma patients receiving cisplatin-based chemotherapy. APMIS 2010, 118(12):941-948. 10.1111/j.1600-0463.2010.02648.x, 21091775.
21. Bellmunt J, Paz-Ares L, Cuello M, Cecere F, Albiol S, Guillem V, Gallardo E, Carles J, Mendez P, de la Cruz J, et al. Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy. Ann Oncol 2007, 18(3):522-528.
22. Matsumura N, Nakamura Y, Kohjimoto Y, Inagaki T, Nanpo Y, Yasuoka H, Ohashi Y, Hara I. The prognostic significance of human equilibrative nucleoside transporter 1 expression in patients with metastatic bladder cancer treated with gemcitabine-cisplatin-based combination chemotherapy. BJU Int 2011, 108(2b):E110-E116. 10.1111/j.1464-410X.2010.09932.x, 21166756.
23. Kawashima A, Nakayama M, Kakuta Y, Abe T, Hatano K, Mukai M, Nagahara A, Nakai Y, Oka D, Takayama H, et al. Excision repair cross-complementing group 1 may predict the efficacy of chemoradiation therapy for muscle-invasive bladder cancer. Clin Cancer Res 2011, 17(8):2561-2569. 10.1158/1078-0432.CCR-10-1963, 21177407.
24. Hoffmann AC, Wild P, Leicht C, Bertz S, Danenberg KD, Danenberg PV, Stohr R, Stockle M, Lehmann J, Schuler M, et al. MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotherapy. Neoplasia 2010, 12(8):628-636. 2915407, 20689757.